Wealthquest Corp Has $368,000 Holdings in Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Wealthquest Corp lessened its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 10.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,532 shares of the biopharmaceutical company’s stock after selling 1,612 shares during the quarter. Wealthquest Corp’s holdings in Pfizer were worth $368,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. North Capital Inc. acquired a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the 4th quarter valued at about $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 2.3%

Pfizer stock opened at $23.27 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a market capitalization of $132.30 billion, a P/E ratio of 16.86, a PEG ratio of 0.86 and a beta of 0.58. The stock has a 50-day simple moving average of $24.36 and a 200 day simple moving average of $24.60.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter last year, the company posted $0.82 earnings per share. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.4%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

Several analysts have issued reports on PFE shares. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. TD Cowen dropped their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. Redburn Atlantic dropped their price target on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.28.

Check Out Our Latest Research Report on Pfizer

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).